Cancer Medicine and Hematology 2017
ACCREDITATION REGISTRATION SCHEDULE FACULTY BROCHURE

Course Description

Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines. Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course provides a comprehensive review of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed upon the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids.

Cancer Medicine and Hematology 2017 is an intensive, 6-day educational activity that is specifically designed to provide clinicians with a comprehensive review of up-to-date practice standards for a broad range of solid tumors, hematologic malignancies, and benign hematologic disorders. Taught by expert Harvard Medical School faculty as well as invited experts, the course features discussion of the most recent clinical trial data, recently updated guidelines, and current expert opinion with impacts on management decisions for patients with these disorders. The highly interactive course is presented through a mixture of engaging lectures followed by question and answer sessions, case-based presentations and panel reviews of participants’ challenging cases, and disease-specific panel discussions. A two-volume syllabus and a thumb drive with copies of each speaker’s outline and slides ensures that clinicians can return to this material again and again as needed to inform and improve their practices, leading to improved patient outcomes.

Course Objectives

Upon completion of this course, participants will be able to:

  • Incorporate new and emerging clinical data into expert recommended best practices for diagnosing, evaluating, and treating patients with breast cancer
  • Develop personalized treatment strategies for patients with lung, head and neck cancers, based on appropriate molecular testing and incorporating newly approved systemic therapies when appropriate
  • Choose from available systemic agents as part of multimodal treatment approaches for patients with gastrointestinal and neuroendocrine cancers based on current molecular testing and risk assessment methods
  • Develop treatment plans for prostate, testicular, renal, and bladder cancers that are tailored to individual patients’ risk factors and characteristics
  • Create evidence-based care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers that incorporate recent advances in diagnosis and management
  • Update treatment practices in a wide range of less common cancers, including brain tumors, thyroid cancer, melanoma, sarcoma, and mesothelioma, based on emerging clinical evidence and current expert recommendations
  • Develop evidence-based management plans for patients with benign hematologic disorders, incorporating new diagnostic strategies and novel therapies into current treatment paradigms
  • Create optimized supportive care and survivorship plans for patients with cancer that take into account recent guidelines and current expert recommendations Course objectives are reviewed annually with the faculty for currency and relevance and refined as necessary by the Course Director and selected physician advisors.

Who Should Attend

The course is directed to specialty physicians.

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 44.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria of the Massachusetts Board of Registration in Medicine for .75 credits of Risk Management Study. Please check your individual state licensing board requirements before claiming these credits.

Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.

ABMS/ACGME Competencies

This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.

IOM Competencies

This course is designed to enhance the following Institute of Medicine competencies: provide patient-centered care, work in interdisciplinary teams, employ evidence-based practice.

Registration Information

Physician fee: $1,600.00
Residents and Fellows in training $1,600.00
Allied Health Professionals $1,600.00
Early Registration Discount Rate $1,350.00
Early Registration Deadline: May 31, 2017

Registration by credit card (VISA, MasterCard or American Express) can be made at http://cmeregistration.hms.harvard.edu/d/m5qm06/4W. Registrations for Harvard Medical School CME programs are made via our secure online registration system. To register for this course, please visit the course website. At the end of the registration process, a Processing (non-refundable service fee) $5 will be added to your registration, and you will have the choice of paying by check or credit card (Visa, MasterCard, or American Express). If you are paying by check, the online registration system will provide you with instructions and a printable form for remitting your course fees by check. Postal, telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. All fees shown in USD.

Inquiries

By phone 617-384-8600, Mon – Fri, 9 am to 5 pm (ET) or by email at: ceprograms@hms.harvard.edu.

Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

Refund Policy

Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will be issued once the conference has started.

Accommodations/Travel

A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116. Telephone: 617-267-5300 until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotel arrangements can also be made online at: https://resweb.passkey.com/go/dfci. Please do not purchase nonrefundable airline ticket(s) until you have received an email from our office confirming your paid registration.

Disclaimer

CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

Schedule

SATURDAY, SEPTEMBER 23
EVENING REGISTRATION 5:30 – 8:30 PM

SUNDAY, SEPTEMBER 24

Presiding: Dr. Mayer

7:00 am Registration
8:45 am Welcome Dr. Mayer
9:00 am Hemophilia-Related Syndromes Dr. Neufeld
10:00 am Leukocyte Disorders Dr. Parnes
11:00 am Break
11:15 am Hemolytic Anemias Dr. Connors
12:15 pm Bone Marrow Failure States Dr. Brodsky
1:15 pm Adjourn/Lunch

Presiding: Dr. Mayer

2:15 pm Thrombocytopenias Dr. Kaushansky
3:15 pm Iron Deficiency and Iron Overload Dr. Fleming
4:00 pm Break
4:15 pm Hemoglobinopathies Dr. Heeney
5:15 pm Advances in Cancer Drug Development Dr. Shapiro
6:15 pm Adjourn

MONDAY, SEPTEMBER 25

Presiding: Dr. Mayer

8:00 am Platelet Function and von Willebrand’s Disease Dr. Handlin
9:00 am Hypercoagulable Syndromes and New Anticoagulant Therapies Dr. Bauer
10:15 am Break
10:30 am Stem Cell Biology and Hematopoietic Growth Factors Dr. Kuter
11:30 am Panel Discussion (Drs. Bauer, Handlin, Kuter)
12:00 pm Lunch

Presiding: Dr. Kuter

1:00 pm Molecular Genetics of Cancer Dr. Wagle
2:00 pm Transfusion Medicine for the Clinician Dr. Dzik
3:00 pm Break
3:15 pm Infections in the Immunocompromised Host Dr. Issa
4:00 pm Biology of Bone Marrow Transplantation Dr. Soiffer
5:00 pm Adjourn

TUESDAY, SEPTEMBER 26

Presiding: Dr. Stone

8:00 am Plasma Cell Neoplasms Dr. Anderson
9:00 am Myelodysplasia Dr. Steensma
9:45 am Acute Myeloid Leukemia Dr. Stone
10:30 am Break
11:00 am Chronic Myeloid Leukemia Dr. DeAngelo
11:45 am Myeloproliferative Syndromes Dr. Tefferi
12:30 pm Panel Discussion (Drs. Anderson, DeAngelo, Steensma, Stone, Tefferi)
1:00 pm Lunch

Presiding: Dr. Stone

2:00 pm Low Grade Lymphoma Dr. Abramson
2:40 pm High Grade Lymphoma Dr. Freedman
3:30 pm Break
3:45 pm Hodgkin’s Disease Dr. LaCasce
4:30 pm CLL and Variants Dr. Byrd
5:15 pm Panel Discussion (Drs. Abramson, Byrd, Freedman, LaCasce)
5:45 pm Adjourn
7:00–9:30 pm 2017 ABIM Maintenance of Certification (MOC) Module Drs. Burstein, DeAngelo, Mayer

WEDNESDAY, SEPTEMBER 27

Presiding: Dr. Griffin

8:00 am Neuroendocrine Tumors Dr. Kulke

Gastrointestinal Malignancies

8:30 am Genetics and Screening Dr. Syngal
9:00 am Esophageal and Gastric Dr. Enzinger
9:45 am Break
10:00 am Pancreas and Hepatobiliary Dr. Ryan
10:45 am Colorectal and Anal Dr. Mayer
11:45 am Panel Discussion (Drs. Enzinger, Kulke, Mayer, Ryan, Syngal)
12:15 pm Lunch

Presiding: Dr. Ryan

1:15 pm Neuro-Oncology Dr. Batchelor
2:15 pm Thymic Tumors and Mediastinal Germ Cell Tumors Dr. Loehrer
3:00 pm Clinical Essentials of Palliative Care Dr. Abrahm
3:40 pm Break
3:55 pm Ovarian Dr. Cannistra
4:55 pm Cervical, Endometrial, Trophoblastic Dr. Matulonis
5:45 pm Panel Discussion (Drs. Cannistra, Matulonis)
6:15 pm Adjourn

THURSDAY, SEPTEMBER 28

Presiding: Dr. Canellos

8:00 am Melanoma Dr. Hodi
9:00 am Thyroid Cancer Dr. Daniels
10:00 am Break
10:15 am Head and Neck Cancer Dr. Haddad

Lung Cancer

11:05 am First Line Non-Small Cell Lung Cancer Dr. Jänne
11:40 am Second and Third Line Non-Small Cell Lung Cancer and Mesothelioma Dr. Sequist
12:15 pm Targeted Therapy for Non-Small Cell and Small Cell Lung Cancer Dr. Shaw
12:45 pm Panel Discussion (Drs. Haddad, Jänne, Sequist, Shaw)
1:00 pm Lunch

Presiding: Dr. Burstein

2:00 pm Sarcoma and GIST Dr. Demetri

Genitourinary Cancer

3:00 pm Testicular Dr. Oh
3:45 pm Break
4:00 pm Renal and Bladder Dr. Chouieri
4:45 pm Prostate Dr. Kantoff
5:45 pm Panel Discussion (Drs. Choueiri, Kantoff, Oh)
6:15 pm Adjourn
7:00–10:00 pm Dinner at the Harvard Club

Topic: “The New Science of Therapeutics”
Speaker: James E. Bradner, MD

FRIDAY, SEPTEMBER 29

Presiding: Dr. Winer
Breast Cancer

8:00 am Survivorship Issues in Breast Cancer and Other Malignancies Dr. Partridge
9:00 am Breast Cancer, Risk, Genetics and Prevention Dr. Garber
9:35 am Pre-invasive Disease, Surgery, Radiation, Hormonal Therapy Dr. Burstein
10:15 am Break
10:30 am Adjuvant and Neoadjuvant Therapy Dr. Winer
11:10 am Metastatic Disease Dr. Krop
11:50 am Panel Discussion (Drs. Burstein, Garber, Krop, Partridge, Winer)
12:15 pm Concluding Remarks Dr. Mayer
Adjourn

Faculty

Janet L. Abrahm, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Jeremy S. Abramson, MD
Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Tracy T. Batchelor, MD, MPH
Giovanni Armenise Harvard Professor of Neurology, Harvard Medical School and Massachusetts General Hospital

Kenneth A. Bauer, MD
Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center

James E. Bradner, MD
President, Novartis Institutes for BioMedical Research

Robert A. Brodsky, MD
Professor of Medicine, Johns Hopkins School of Medicine and Chief of Hematology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Harold J. Burstein, MD, PhD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

John C. Byrd, MD
Professor Medicine and Medicinal Chemistry, Ohio State University

George P. Canellos, MD
William Rosenberg Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Stephen A. Cannistra, MD
Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center

Toni K. Choueiri, MD
Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Jean M. Connors, MD
Assistant Professor Medicine, Harvard Medical School and Brigham and Women’s Hospital

Gilbert H. Daniels, MD
Professor of Medicine, Harvard Medical School and Massachusetts General Hospital

Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

George D. Demetri, MD
Professor of Medicine, Harvard Medical School and Dana Farber Cancer Institute

Walter H. Dzik, MD
Associate Professor of Pathology, Harvard Medical School and Massachusetts General Hospital

Peter C. Enzinger, MD
Assistant Professor of Medicine, Harvard Medical School and Dana Farber Cancer Institute

Mark D. Fleming, MD, PhD
S. Burt Wolbach Professor of Pathology, Harvard Medical School and Children’s Hospital Boston

Arnold S. Freedman, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Judy E. Garber, MD, MPH
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

James D. Griffin, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Robert I. Haddad, MD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Robert I. Handin, MD
Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital

Matthew M. Heeney, MD
Assistant Professor of Pediatrics, Harvard Medical School and Boston Children’s Hospital

F. Stephen Hodi, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Nicolas C. Issa, MD
Assistant Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital

Pasi A. Jänne, MD, PhD
Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute

Bruce E. Johnson, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Philip W. Kantoff, MD
Chairman of Medicine and George J. Bosl Chair in Medicine, Memorial Sloan Kettering Cancer Center

Kenneth Kaushansky, MD
Senior Vice President of the Health Sciences and Dean of the School of Medicine, Stony Brook University,
Stony Brook, New York

Ian E. Krop, MD, PhD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Matthew H. Kulke, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

David J. Kuter, MD, DPhil
Professor of Medicine, Harvard Medical School and Massachusetts General Hospital

Ann S. LaCasce, MD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Patrick J. Loehrer, Sr, MD
Director, Indiana University Melvin and Bren Simon Cancer Center, H.H. Gregg Professor of Oncology and Associate Dean for Cancer Research, Indiana University School of Medicine

Ursula A. Matulonis, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Robert J. Mayer, MD
Stephen B. Kay Family Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Ellis J. Neufeld, MD, PhD
Clinical Director, Physician-in-Chief and Executive Vice President, St. Jude Children’s Research Hospital, Memphis, Tennessee

William K. Oh, MD
Professor of Medicine and Urology, Mount Sinai School of Medicine and Chief, Division of Hematology-Oncology, Mount Sinai Comprehensive Cancer Center, New York, New York

Aric D. Parnes, B.Ch.
Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Ann H. Partridge, MD, MPH
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

David P. Ryan, MD
Professor of Medicine, Harvard Medical School and Massachusetts General Hospital

Lecia V. Sequist, MD
Landry Family Associate Professor of Medicine in the Field of Medical Oncology, Harvard Medical School, Massachusetts General Hospital

Geoffrey I. Shapiro, MD, PhD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Alice T. Shaw, MD, PhD
Associate Professor of Medicine, Harvard Medical School and Massachusetts General Hospital

Robert J. Soiffer, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

David P. Steensma, MD
Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Richard M. Stone, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Sapna Syngal, MD, MPH
Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital

Ayalew Tefferi, MD
Professor of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota

Nikhil Wagle, MD
Assistant Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute

Eric P. Winer, MD
Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute


Copyright © 2017, Harvard Medical School
Last update 4.11.2017